Repogen

Quick links to important sections

Repogen

Treatment option:

Medically reviewed

Rosario Oropesa

Last updated on 22/12/2025

This page provides general, reference-level information compiled from official medical sources. It is not a substitute for professional medical advice, diagnosis, or treatment. For decisions about your health, please consult a qualified healthcare professional.

Overview of Repogen

Property Description
Active ingredients Estrogens, Conjugated (CE) and Medroxyprogesterone Acetate (MPA)
Form Oral tablet
Pharmacological class Hormone Replacement Therapy (HRT); Estrogen and Progestin Combination
General purpose Hormone restoration and management of estrogen deficiency symptoms
Origin Derived from natural estrogens (CE) and a synthetic progestin (MPA)

Repogen, representing the Conjugated Estrogens and Medroxyprogesterone Acetate combination, is a prescription-only hormonal medication classified as a single combination product within the therapeutic category of Hormone Replacement Therapy (HRT). It is manufactured as an oral tablet and designed for the oral route of administration. This pharmaceutical preparation is defined by its strategic, fixed combination of two primary sex hormones, which differentiates it from therapies that utilize only a single hormone component.


Repogen: Classification as a Combined Hormone Replacement Therapy

This combination belongs to the specific pharmacological class of Estrogen and Progestin Combination therapies, a segment of Hormone Replacement Therapy (HRT). This dual-component approach is utilized for its balancing mechanism. This product is notably differentiated by its intended patient group: it is specifically formulated for use in postmenopausal women with an intact uterus. This design is a key feature that prevents this medicine from being used as monotherapy, as the necessary presence of the progestin dictates the target demographic.


Composition: Why It Contains Both Estrogens, Conjugated and Medroxyprogesterone

The active ingredients are Estrogens, Conjugated (CE) and Medroxyprogesterone Acetate (MPA). The CE component, known to contain multiple forms of estrogens, has origins partially derived from naturally occurring sources, contrasting with the purely synthetic origin of the progestin, MPA. This engineering utilizes the distinct physiological actions of both compounds. The progestin balance afforded by the MPA is intended to counteract the potential stimulating effect of the estrogen on the uterine lining, thereby preventing endometrial hyperplasia. This combination strategy is a key differentiation factor from Conjugated Estrogens monotherapy, ensuring a comprehensive profile for hormone restoration.


The General Purpose of This Dual Hormonal Action

The general therapeutic purpose of this fixed-dose combination is hormone restoration, aimed at stabilizing the systemic physical and physiological discomforts arising from estrogen deficiency after menopause. By restoring hormone levels, the dual hormonal action addresses the fundamental cause of symptoms. This approach is typically used when a patient seeks to manage generalized postmenopausal changes, ensuring that the necessary estrogen replacement is therapeutically effective while the inclusion of the progestin provides structural protection for the uterus.

What side effects are possible with Repogen?

Possible Side Effects and Safety Information

Repogen, a topical blend of lanolin, beeswax, and olive oil, is generally considered safe and well-tolerated when used as directed to help alleviate symptoms associated with nipple fissures in breastfeeding mothers. Clinical studies specifically evaluating the use of Repogen cream have reported no maternal or neonatal adverse effects attributable to the intervention throughout the study period. Furthermore, no instances of skin irritation, allergic responses, or feeding complications related to the cream were documented in these trials.


General Safety and Warnings

As with any topical product, there is always a potential for individual sensitivity to one of the components. Although rare, a serious allergic reaction to the constituents of the cream could occur. The product contains lanolin, beeswax, and olive oil.

  • Hypersensitivity: Discontinue use and seek medical advice if you experience signs of an allergic reaction such as rash, itching, swelling, severe dizziness, or trouble breathing.
  • Infant Feeding: Clinical data indicated no significant differences in infant defecation-based feeding sufficiency. However, a slight decrease in the wet diaper count was noted in infants of mothers using Repogen, though this was not considered an adverse event. It is important to continue monitoring the infant’s overall feeding sufficiency and consult a healthcare professional if there are any concerns.

Summary of Observed Effects

Reported effects of Repogen in clinical trials have primarily focused on its efficacy, which includes a reduction in nipple pain, redness, and wounds compared to a control group. No common adverse effects have been reported that are specific to the use of this cream.

Overdose and Emergency Response

Overdose and When to Seek Help

Overdosage with Repogen (a combination of Conjugated Estrogens and Medroxyprogesterone Acetate) is associated with a defined profile of clinical manifestations, as documented in official regulatory prescribing information. The symptoms primarily relate to the gastrointestinal and reproductive systems, and are generally classified as non-severe.


Documented Manifestations

Acute excess exposure may result in non-severe clinical signs. These documented overdose presentations include nausea and vomiting. Other reported systemic symptoms are abdominal pain, breast tenderness, drowsiness, and fatigue. In women, withdrawal bleeding may occur as a specific physiological response following acute excess exposure to the hormones.


Required Emergency Actions

The official treatment strategy mandates the discontinuation of Repogen therapy immediately upon diagnosis. Management requires the institution of appropriate symptomatic care for the presenting clinical signs, as regulatory information confirms that no specific antidote is known for this hormonal combination. Individuals must seek immediate medical attention or call a Poison Help line upon suspected overdose. Urgent medical services must be contacted immediately if the person shows critical signs such as collapse, a seizure, trouble breathing, or the inability to be awakened.

Therapeutic Uses of Repogen

Repogen, a combination of Conjugated Estrogens and Medroxyprogesterone Acetate, is applied across several key therapeutic domains. It is relevant in contexts involving chronic estrogen deficiency and is commonly used in postmenopausal women with an intact uterus for hormone restoration. It is considered relevant in the management of distressing symptoms and for long-term preventative support.

The therapy is applied in addressing conditions presenting with symptomatic discomfort and localized manifestations. This includes the management of moderate to severe vasomotor symptoms (hot flashes and night sweats), the treatment of symptoms associated with Genitourinary Syndrome of Menopause (GSM), and the prevention of postmenopausal osteoporosis. The use of Repogen provides supportive relief during symptomatic periods.


Summary of Symptomatic Support

This medication is applied in clinical settings that involve heightened systemic burden. It plays a role in managing symptoms related to physical discomfort.


Core Therapeutic Benefit

This benefit contributes to easing the overall symptom load, helping to manage symptoms that interfere with daily functioning and may assist with maintaining functional stability. It is often used in patient groups like women with Premature Ovarian Insufficiency (POI) or those who have had early surgical menopause, where hormone restoration is commonly applied in addressing systemic manifestations associated with early and prolonged estrogen lack.

Eligibility and Restrictions for Use

Eligibility: Who Can and Cannot Use Repogen?

Repogen (Conjugated Estrogens / Medroxyprogesterone Acetate) is officially designated for use exclusively in postmenopausal women with an intact uterus who require hormone replacement therapy. Eligibility is determined by strict non-use criteria, as defined in government regulatory labeling.

Absolute Non-Eligibility (Contraindications)

Repogen is contraindicated and must not be used in women who have or have a history of:

  • Breast cancer or any estrogen-dependent neoplasia.
  • Thromboembolic disorders (e.g., deep vein thrombosis, pulmonary embolism, stroke, or myocardial infarction).
  • Undiagnosed abnormal genital bleeding.
  • Known hepatic impairment or liver disease.
  • Known or suspected pregnancy.

Restricted and Age-Related Eligibility

Use is not indicated for pediatric populations. While permitted for adults, the medicine is subject to regulatory warnings for women 65 years of age and older due to an increased risk of probable dementia reported in this age group.

Additionally, use is prohibited when the sole objective is the prevention of cardiovascular disease or dementia. The regulatory label also advises against use during lactation, as it may diminish the quality and quantity of breast milk.

What should I know about interactions with other medicines?

Repogen Interactions with Other Medicines and Products

Interactions with Repogen have been officially documented, potentially leading to changes in the concentration of Repogen in the body or additive pharmacodynamic effects. Healthcare providers should be informed of all medicines, supplements, and herbal products currently being used.

Pharmacokinetic Interactions

Repogen is metabolized by the enzyme CYP3A4 and is a substrate for the transporter protein P-glycoprotein (P-gp). Co-administration with products that interfere with these pathways can significantly alter Repogen exposure.

  • CYP3A4 Inhibitors (e.g., ketoconazole): Concomitant use with strong inhibitors can substantially increase the level of Repogen in the bloodstream, often necessitating a reduction in the Repogen dose to mitigate potential effects.
  • CYP3A4 Inducers (e.g., rifampin): Co-administration with strong inducers can decrease Repogen blood levels, which may result in a loss of clinical effectiveness. This combination is generally not recommended.

Pharmacodynamic Interactions

Repogen is known to prolong the QTc interval, a measure of the heart's electrical activity. Combining it with other medicinal products that also prolong the QTc interval increases the risk of serious ventricular arrhythmias. Therefore, co-administration with other QTc-prolonging agents requires careful clinical assessment and monitoring by a healthcare professional.

Mechanism of Action

Repogen functions as a dissociative non-glucocorticoid steroid receptor ligand that preferentially targets and accumulates in skeletal muscle and adipose tissue.

Its primary biological target is the intracellular glucocorticoid receptor (GR). Repogen acts as an agonist at the GR binding domain, but it promotes a distinct conformational change in the receptor complex compared to traditional glucocorticoids. This specific conformation favors the dissociation of the ligand-GR complex from the inhibitory nuclear factor-kappa B (NF-κB) transcription factor pathway.

This molecular pathway modulation leads to a reduced capacity for the liganded GR to induce the transcription of pro-inflammatory genes that are regulated by NF-κB. Conversely, the specific Repogen-GR complex retains the capacity to transactivate certain anti-inflammatory and muscle-stabilizing genes.

The resulting intracellular consequence is a shift in the cellular signaling environment away from catabolic and inflammatory processes. The downstream cascade involves the relative upregulation of genes encoding proteins that support cell membrane integrity and metabolic regulation, and the relative downregulation of various inflammatory mediators.

This targeted system-level physiological modulation occurs by favoring anabolic signaling and mitigating inflammatory cascade propagation within the selective tissues.

Dosage and Administration Information

How to Use Repogen: Official Administration Guidelines

Repogen, a fixed-dose combination of Conjugated Estrogens and Medroxyprogesterone Acetate, is administered exclusively by the oral route as a tablet. The official prescribing protocol typically follows a Continuous Combined Regimen where one tablet is taken once daily without interruption, maintaining a steady hormone level throughout the cycle. Treatment initiation is generally recommended at the lowest available fixed-dose strength, such as the 0.45 mg CE/1.5 mg MPA combination, to ensure adherence to the principle of utilizing the lowest effective dose.


Dosing and Scheduling Rules

Feature Official Instruction
Dosing Frequency One tablet taken once daily (QD).
Timing May be taken with or without food, but should be ingested at the same time each day to support consistent plasma levels.
Duration Principle Use must be for the shortest duration consistent with the individual's therapeutic goals, requiring periodic re-evaluation.
Missed Dose If a dose is missed, it should be taken as soon as it is remembered. However, if it is nearly time for the next scheduled dose, the missed tablet should be skipped to prevent doubling the dose.
Population Use No specialized dose adjustment is formally required for older adults; usage follows the general adult principle of the lowest effective dose.

This standardized administration procedure ensures the consistent use of the combined therapy. The regimen emphasizes consistency of timing and adherence to the principle of minimal effective dosing over time.

Recent Clinical Evidence

Research evidence / Overview of studies for Repogen


Evidence for use in Vasomotor Symptom Management

The research explored outcomes related to patient-reported experiences (hot flashes and night sweats) primarily using Randomized Controlled Trials (RCTs). These studies were used in research exploring how symptoms change over time in postmenopausal women with an intact uterus. Researchers examined outcomes related to physical discomfort by closely monitoring symptom frequency and intensity, often using patient diaries over periods of typically 12 weeks to one year.

Findings describe patterns observed in the studies related to these episodic or acute changes. Research highlights changes measured during the study period for both the frequency and the severity of these discomforts. These outcomes reflecting daily functioning or activity level were observed in the studied populations.


Evidence for Preventing Postmenopausal Osteoporosis

The evidence base for this combination was studied for outcomes related to postmenopausal osteoporosis using large-scale, long-term Randomized Controlled Trials (RCTs), including components of major government-sponsored research initiatives. These studies explored long-term structural outcomes and monitored outcomes reflecting daily functioning or activity level in the observed populations. The trials monitored outcomes related to systemic or functional imbalance by tracking changes in Bone Mineral Density (BMD) at the hip and spine, as well as the occurrence rates of fractures over many years.

Data show patterns related to BMD measurements and observed fracture outcomes in the observed populations. Research suggests that the combination was observed in long-term research scenarios, contributing to the broader evidence landscape on bone health.


Evidence for Genitourinary Syndrome of Menopause (GSM)

Research explored outcomes related to Genitourinary Syndrome of Menopause (GSM) using short-term to intermediate RCTs. Studies focused on outcomes linked to inflammatory or irritative states (vulvovaginal symptoms), exploring both patient-reported outcomes describing perceived discomfort (like vaginal dryness and painful intercourse) and objective outcomes like changes in tissue markers (e.g., vaginal pH).

Findings indicate patterns related to both the objective markers and the patient-reported outcomes describing perceived discomfort. Research provides insight into short-term changes, documenting how these outcomes evolved in the observed populations during the initial months of study.


Key Uncertainties and Research Gaps

Despite the established evidence base for key indications, several research limitations are noted in the scientific literature. Comparative evidence is lacking, as many trials compare the combination to an inactive substance (placebo) rather than to alternative hormonal or non-hormonal therapies. The most extensive long-term data apply only to the populations studied and often reflect a single, fixed dosage. Consequently, there is limited information for long-term outcomes and duration of measured effect in certain patient subgroups, and research describes group patterns, not personal outcomes.

Frequently Asked Questions (FAQ)

Common questions about Repogen (FAQ)

Q: What is the difference between Repogen and other similar drugs I see advertised?

A: Repogen is an approved combination hormone therapy product that contains two specific active ingredients: conjugated estrogens and medroxyprogesterone acetate. According to regulatory documents, this fixed combination is indicated strictly for use in postmenopausal women who still have an intact uterus. This specific composition and approved indication distinguish it from other single-ingredient or different-combination products.

Q: Is it common to feel tired when first starting Repogen?

A: Official product information notes that fatigue (feeling tired), a lack of strength, and drowsiness have been reported in clinical studies. Additionally, these symptoms may be mentioned in the context of taking more than the prescribed amount. If fatigue becomes severe or persistent, official guidance recommends seeking the advice of a healthcare provider.

Q: Are there any specific foods or drinks that should be avoided with Repogen?

A: The drug is known to be metabolized by a specific enzyme system in the body called CYP3A4. Certain foods and beverages, such as grapefruit products, may interfere with this enzyme and change how much medicine is absorbed into the body. The potential for this interaction highlights why metabolic factors are considered when using this medication.

Q: Can Repogen affect my ability to drive or operate machinery?

A: The potential for effects on the nervous system and vision is noted in the official safety information. Side effects like dizziness, migraines, or visual changes, including sudden loss of vision, have been reported. When these kinds of effects are experienced, they are noted as potentially affecting the ability to drive or operate machinery.

Q: Does Repogen require special monitoring like blood tests?

A: Yes, regulatory information recommends periodic monitoring while taking this medication. Specifically, a healthcare provider may check metrics like blood pressure, blood glucose (sugar) levels, lipid profiles (fats in the blood), and thyroid function.

Q: What is the most frequently reported side effect of Repogen?

A: Based on data from clinical trials submitted to regulatory authorities, the most frequently reported side effects observed include headache, breast pain or tenderness, and abdominal pain.

Q: Can Repogen be taken with common over-the-counter pain relievers?

A: The official label provides comprehensive warnings regarding medications that can affect how the body breaks down the product. This applies to any drugs that interact with the product's metabolism (CYP3A4/P-gp) or other key physiological systems. The full product information lists specific drug classes that interact with the product's metabolism.

Q: Do studies suggest Repogen is generally well-tolerated?

A: Clinical trial data lists the reported side effects and provides statistics on how often they occurred, as well as the rate at which patients discontinued the study due to those reactions. This information is available in official product documents and helps describe the medicine's tolerability profile as observed during research.

Q: Are there any known severe or less common side effects associated with Repogen?

A: Yes, official product information includes a Boxed Warning—the most serious level of warning—about certain severe risks. These risks reported in studies include an increased chance of developing blood clots (such as Deep Vein Thrombosis and Pulmonary Embolism), stroke, heart attack, and an increased risk of breast cancer.

Q: Does Repogen interact with common supplements like multivitamins or fish oil?

A: Official drug interaction sections primarily focus on prescription medications that significantly impact the drug's metabolism or effects. While common supplements are typically not listed as major contraindications, this general warning about metabolic interactions means that sharing a complete list of all supplements with a healthcare provider is generally recommended.

Q: Can I stop taking Repogen once my symptoms improve?

A: Official guidelines state that this product should be used for the shortest duration consistent with treatment goals. Periodic re-evaluation is necessary to confirm if continued treatment aligns with current therapeutic goals.

Q: Is there a generic version of Repogen available?

A: The combination of the active ingredients, conjugated estrogens and medroxyprogesterone acetate, is available under the Repogen brand name. According to the FDA, there is currently no approved generic equivalent for this specific fixed-dose combination product in the U.S.

Q: Can Repogen cause problems with sleep?

A: Yes, official safety information indicates that insomnia, or difficulty sleeping, has been reported as a common side effect in clinical trials.

Q: Is Repogen effective for other conditions besides the main one it treats?

A: Official regulatory documents explicitly state the approved indications for the drug. These are limited to treating moderate-to-severe hot flashes (vasomotor symptoms), treating vulvar and vaginal atrophy, and the prevention of postmenopausal osteoporosis.

Q: What happens when Repogen leaves the body?

A: According to the official pharmacokinetics section, the active ingredients are broken down primarily in the liver. Once metabolized, the resulting substances are mostly eliminated from the body through the urine.

Q: Is the list of side effects in the leaflet common for everyone?

A: The side effect lists in official documentation reflect the frequency with which these effects were observed in clinical trials (e.g., common, uncommon, or rare). This incidence data helps describe the risk across a group of people, but does not predict whether any single patient will experience a specific side effect.

Q: Can Repogen affect my mood?

A: Yes, official adverse reaction reports include mood changes among the potential side effects. These reported changes specifically include depression and emotional lability, which refers to rapid, often exaggerated changes in mood.

Q: What should I do if a side effect seems to be getting worse?

A: Official safety warnings describe when a healthcare provider should be contacted immediately, such as if specific serious symptoms occur or if any other side effect is concerning.

Q: Is Repogen available in different strengths?

A: Yes, the product is manufactured and approved in multiple fixed-dose strengths, which contain varying amounts of the estrogen and progestin combination.

Q: Can Repogen cause weight change?

A: Official post-marketing and clinical trial data report both weight increases and weight decreases as possible side effects. Fluid retention, known as edema, has also been reported.

Q: Are there different brand names for the active ingredient in Repogen?

A: The two active ingredients, conjugated estrogens and medroxyprogesterone acetate, are components that can be found in various other brand-name products. Repogen is one specific brand name for the fixed-dose combination of these two ingredients.

Q: What is the mechanism of action of Repogen explained simply?

A: The official mechanism of action explains that the estrogen component helps replace the hormone that is deficient after menopause. The progestin component (medroxyprogesterone acetate) is included to protect the lining of the uterus, counteracting the effects of the estrogen to reduce the risk of endometrial overgrowth.

Q: Can Repogen be taken by people with kidney issues?

A: Official warnings advise caution for all patients with conditions that may be affected by fluid retention, which can include kidney diseases. Patients with these conditions are generally subject to close monitoring.

Q: Is it normal to not feel any change after starting Repogen?

A: The evaluation of effectiveness in clinical studies often measures full therapeutic effect over several weeks to months. This suggests that a noticeable improvement in symptoms may not be immediate after beginning the medication.

How should Repogen be stored and disposed of?

How to Store and Dispose of Repogen

Repogen (conjugated estrogens/medroxyprogesterone acetate) tablets must be handled and stored according to official regulatory requirements to maintain product stability.

Storage Conditions

Requirement Official Instruction
Temperature Store at Controlled Room Temperature (20 C to 25 C / 68 F to 77 F)
Protection Store away from excess heat and moisture; keep from freezing
Container Keep the container tightly closed
Child Safety Keep out of the sight and reach of children

Disposal Instructions

Unused or expired Repogen must not be kept. Disposal should be managed through a drug take-back program when available. Otherwise, mix the product with an undesirable substance and discard it in household trash, following official guidance. Users must consult a healthcare professional for specific disposal advice.

Attention! Always consult to a doctor or pharmacist before using pills or medicines.

Available in countries:

Equivalent of Repogen found in:

A-Z Index: